Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A
2(40.0%)
Phase 1
1(20.0%)
Early Phase 1
1(20.0%)
Phase 2
1(20.0%)
5Total
N/A(2)
Phase 1(1)
Early Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06239636Early Phase 1Recruiting

First-in-human Safety Study of Hypoimmune Pancreatic Islet Transplantation in Adult Subjects With Type 1 Diabetes

Role: lead

NCT03635437Phase 1Completed

Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes

Role: lead

NCT02617654Phase 2Completed

Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes

Role: lead

NCT02984514Not ApplicableCompleted

Brown Adipose Tissue in Type 1 Diabetes

Role: lead

NCT02967354Not ApplicableCompleted

[11C]5-Hydroxy-tryptophan PET for Assessment of Islet Mass in Type 2 Diabetes

Role: lead

All 5 trials loaded